These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19169664)

  • 1. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.
    Coletta DK; Sriwijitkamol A; Wajcberg E; Tantiwong P; Li M; Prentki M; Madiraju M; Jenkinson CP; Cersosimo E; Musi N; Defronzo RA
    Diabetologia; 2009 Apr; 52(4):723-32. PubMed ID: 19169664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
    Coletta DK; Fernandez M; Cersosimo E; Gastaldelli A; Musi N; DeFronzo RA
    Diabet Med; 2015 May; 32(5):657-64. PubMed ID: 25484175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
    Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
    Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
    Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
    Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
    Bandyopadhyay GK; Yu JG; Ofrecio J; Olefsky JM
    Diabetes; 2006 Aug; 55(8):2277-85. PubMed ID: 16873691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Baig R; Suraamornkul S; Hardies LJ; Coletta DK; Cline GW; Monroy A; Koul S; Sriwijitkamol A; Musi N; Shulman GI; DeFronzo RA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1916-23. PubMed ID: 20157197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.
    Kubota N; Terauchi Y; Kubota T; Kumagai H; Itoh S; Satoh H; Yano W; Ogata H; Tokuyama K; Takamoto I; Mineyama T; Ishikawa M; Moroi M; Sugi K; Yamauchi T; Ueki K; Tobe K; Noda T; Nagai R; Kadowaki T
    J Biol Chem; 2006 Mar; 281(13):8748-55. PubMed ID: 16431926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.
    Skov V; Glintborg D; Knudsen S; Tan Q; Jensen T; Kruse TA; Beck-Nielsen H; Højlund K
    PLoS One; 2008 Jun; 3(6):e2466. PubMed ID: 18560589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
    Bajaj M; Suraamornkul S; Pratipanawatr T; Hardies LJ; Pratipanawatr W; Glass L; Cersosimo E; Miyazaki Y; DeFronzo RA
    Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin stimulates lipid metabolism via AMPK in rabbit blastocysts.
    Schindler M; Pendzialek M; Grybel KJ; Seeling T; Gürke J; Fischer B; Navarrete Santos A
    Hum Reprod; 2017 Jul; 32(7):1382-1392. PubMed ID: 28472298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
    Wallace TM; Levy JC; Matthews DR
    Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo.
    Saha AK; Avilucea PR; Ye JM; Assifi MM; Kraegen EW; Ruderman NB
    Biochem Biophys Res Commun; 2004 Feb; 314(2):580-5. PubMed ID: 14733947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.
    Hammarstedt A; Pihlajamäki J; Graham TE; Kainulainen S; Kahn BB; Laakso M; Smith U
    J Intern Med; 2008 Apr; 263(4):440-9. PubMed ID: 18324929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ratio of leptin to adiponectin can be used as an index of insulin resistance.
    Oda N; Imamura S; Fujita T; Uchida Y; Inagaki K; Kakizawa H; Hayakawa N; Suzuki A; Takeda J; Horikawa Y; Itoh M
    Metabolism; 2008 Feb; 57(2):268-73. PubMed ID: 18191059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.